Most Read Articles
5 days ago
A strong belief in the necessity of medication is associated with better adherence to oral disease-modifying antirheumatic drugs (DMARDs) or prednisone, while higher self-efficacy correlates with poor adherence, in a diverse cohort of patients with rheumatoid arthritis (RA), suggests a study.
4 days ago
Low-dose administrations of haloperidol after thoracic surgery does not appear to prevent postoperative delirium, according to a new study.
2 days ago
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.
Pearl Toh, 4 days ago
Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.

Maintenance therapy with difluoromethylornithine safe, effective in high-risk neuroblastoma

09 Oct 2018

Difluoromethylornithine (DFMO) maintenance medication in high-risk neuroblastoma (HRNB) patients is associated with better survival outcomes, a recent study has shown.

The study included HRNB patients with histologically confirmed disease who took maintenance DFMO to prevent relapse following completion of standard therapy (stratum 1; n=101; mean age 3.5 years; 56 percent male) or after salvage therapy for relapsed disease (stratum 2; n=39; mean age 3.2 years; 72 percent male).

Over a median follow-up period of 3.5 years, participants in stratum 1 demonstrated a mean 2-year event-free survival rate of 84.4±4 percent. Overall survival was likewise high at 97±2 percent. Survival rates remained high even in patients with high-risk features such as status of the MYCN gene.

In the subset of stratum 1 participants who were given DFMO after the completion of the Children’s Oncology Group antibody clinical trial, event-free and overall survival rates were also high (86±4 percent and 97±2 percent).

In stratum 2, the 2-year event-free and overall survival rates were low at 51±8 percent and 84±6 percent, respectively. These values were lower in patients with relapsed disease (35±11 percent and 80±9 percent, respectively) and higher in those with primary refractory disease (68±11 percent and 89±7 percent, respectively).

In terms of safety, no serious adverse events were reported. Majority (67 percent) of the patients reported no treatment-related adverse events. Grade 2–3 transaminitis was the most common adverse event, and none of the cases required suspension of the DFMO treatment.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
5 days ago
A strong belief in the necessity of medication is associated with better adherence to oral disease-modifying antirheumatic drugs (DMARDs) or prednisone, while higher self-efficacy correlates with poor adherence, in a diverse cohort of patients with rheumatoid arthritis (RA), suggests a study.
4 days ago
Low-dose administrations of haloperidol after thoracic surgery does not appear to prevent postoperative delirium, according to a new study.
2 days ago
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.
Pearl Toh, 4 days ago
Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.